Sustainable Insight Capital Management LLC Sells 15,488 Shares of Humana Inc. (NYSE:HUM)

Sustainable Insight Capital Management LLC reduced its holdings in Humana Inc. (NYSE:HUMFree Report) by 38.9% in the 4th quarter, Holdings Channel reports. The fund owned 24,342 shares of the insurance provider’s stock after selling 15,488 shares during the quarter. Humana accounts for 2.7% of Sustainable Insight Capital Management LLC’s portfolio, making the stock its 13th biggest position. Sustainable Insight Capital Management LLC’s holdings in Humana were worth $6,176,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Creative Financial Designs Inc. ADV boosted its stake in Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 61 shares during the period. Atwood & Palmer Inc. bought a new position in shares of Humana during the third quarter worth about $29,000. Ashton Thomas Securities LLC acquired a new stake in Humana in the 3rd quarter valued at approximately $31,000. Your Advocates Ltd. LLP lifted its stake in Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares in the last quarter. Finally, LRI Investments LLC boosted its position in Humana by 1,021.4% during the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock worth $50,000 after acquiring an additional 143 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Insider Activity at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.32% of the stock is currently owned by insiders.

Humana Price Performance

Shares of Humana stock opened at $293.22 on Friday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $35.31 billion, a price-to-earnings ratio of 25.97, a price-to-earnings-growth ratio of 2.15 and a beta of 0.55. The company has a 50-day simple moving average of $273.81 and a two-hundred day simple moving average of $305.88. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $411.80.

Humana (NYSE:HUMGet Free Report) last released its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Analysts forecast that Humana Inc. will post 16.11 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on HUM. Oppenheimer lowered their price objective on shares of Humana from $400.00 to $280.00 and set an “outperform” rating on the stock in a report on Thursday, October 3rd. Royal Bank of Canada decreased their price objective on Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. TD Cowen lifted their target price on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. UBS Group reduced their price target on Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, October 4th. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a research note on Thursday, October 3rd. Twenty investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Humana currently has an average rating of “Hold” and an average target price of $302.80.

Read Our Latest Research Report on Humana

Humana Profile

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMFree Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.